Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A Human induced pluripotent stem cell (iPSC) line was generated from dermal fibroblasts of a patient affected with an autosomal recessive retinal dystrophy carrying the homozygous c.910-7G>A variant in UBAP1L. Three isogenic control iPSC lines derived from this affected subject line were created using CRISPR/Cas9 engineering. All iPSC lines expressing the pluripotency markers, were able to differentiate into the three germ layers, and exhibit a normal karyotype. These cellular models will provide a powerful tool to study disease mechanisms associated with the recently reported UBAP1L- associated retinal dystrophy and better understand the role of the protein in retinal physiology.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.scr.2024.103558 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ACQUIRED TORPEDO-LIKE MACULOPATHY ASSOCIATED WITH MACULAR NEOVASCULARIZATION IN BEST VITELLIFORM MACULAR DYSTROPHY.
Retina
September 2025
Retinal Heredodystrophies Unit, Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Cortical response to transient and long-term visual field loss.
Cereb Cortex
August 2025
Nencki Institute of Experimental Biology, PAS, 3 Pasteur Street, 02-093 Warsaw, Poland.
In the visual cortices, receptive fields (RFs) are arranged in a gradient from small sizes in the center of the visual field to the largest sizes at the periphery. Using functional magnetic resonance imaging (fMRI) mapping of population RFs, we investigated RF adaptation in V1, V2, and V3 in patients after long-term photoreceptor degeneration affecting the central (Stargardt disease [STGD]) and peripheral (Retinitis Pigmentosa [RP]) regions of the retina. In controls, we temporarily limited the visual field to the central 10° to model peripheral loss.
View Article and Find Full Text PDFTruncating Mutations in BBS10 and BBS12 Impair Proteostasis and Ciliary Architecture in Bardet-Biedl Syndrome.
Exp Eye Res
September 2025
Department of Ophthalmology, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Henan Eye Hospital, Zhengzhou, Henan, China; Henan Key Laboratory of Ophthalmology and Visual Science, Henan Eye Hospital, Henan Provincial People's Hospital, Zhengzhou, Henan, China; Eye institu
Bardet-Biedl Syndrome (BBS) is a rare autosomal recessive ciliopathy characterized by genetic heterogeneity. Despite significant progress in understanding the BBSome-coding genes associated with ciliopathies, the pathogenesis linked to mutations in chaperonin-coding genes (BBS6, BBS10, and BBS12) remains poorly defined. This study aims to confirm the genetic diagnosis of BBS and elucidate the pathological mechanisms in causative genes of BBS10 and BBS12.
View Article and Find Full Text PDFEfficacy and Safety of Voretigene Neparvovec in -Retinopathy: Results of a Phase III Trial in Japan.
Ophthalmol Sci
July 2025
Japan Community Healthcare Organization, Tokyo, Japan.
Purpose: We report the efficacy and safety of voretigene neparvovec (VN) as an adeno-associated viral vector-based gene therapy for Japanese patients with inherited retinal dystrophy caused by biallelic pathogenic variants (-retinopathy).
Design: Open-label, single arm, phase III clinical trial.
Participants: Four subjects were recruited based on the following criteria: (1) a clinical and molecular genetic diagnosis of -retinopathy; (2) age ≥4 years; (3) a best-corrected VA (BCVA) worse than 20/60 or a visual field (VF) <20° by a III4e isopter or equivalent; and (4) sufficient viable retinal cells by OCT or ophthalmoscopy.
Evaluating the long-term efficacy of umbilical cord-derived mesenchymal stem cell therapy in retinitis pigmentosa: findings from a 1-to-4-year follow-up.
Stem Cells Transl Med
July 2025
Professor in Hematology Department and Bone Marrow Transplantation Center at Erciyes University, Kayseri 38039, Turkiye.
Background: The objective of this study was to assess the long-term effectiveness and safety of implanting mesenchymal stem cells derived from umbilical cord tissue (UC-MSC) in patients diagnosed with retinitis pigmentosa (RP).
Methods: In this single-center study with a retrospective design, 669 eyes received suprachoroidal implantation of 5 million UC-MSCs. Postoperative assessments were conducted on the first day, third month, and every 6 months thereafter.